DA Davidson analyst Linda Bolton Weiser initiated Nu Skin (NUS) with a Buy rating and a price target of $92, forecasting a 13% organic sales growth and 24% earnings growth in FY18. The analyst notes the achievements of the company's new CEO and CFO in shifting its focus to customer acquisition through "engaging Platforms that leverage social selling, enabling Products that are demonstrable online, and empowering programs to optimize sales performance." Weiser also points to Nu Skin's attractive valuation at 9.0-times her expected FY19 EBITDA - a discount to Herbalife (HLF) and USANA (USNA) which trade around 11-times.